The 2023 Novel Therapies for Type 2 Diabetes & Obesity Summit
We put a spotlight on disease-modifying therapies beyond managing blood sugar, optimizing oral delivery of GLP-1 receptor agonists, and investigating clinical progress in combining incretin-based therapies, the Novel Therapies for Type 2 Diabetes & Obesity Summit is uniquely positioned to carve out a new pathway in metabolic disorders.
We heard from industry experts unravelling multi-morbidity metabolic disorders with deep-learning models, learning from clinical setbacks to accelerate treatment in targeted patient subgroups, and delineating clinical endpoints to demonstrate clinical benefit beyond bariatric surgery.
Aligned preclinical optimization of GLP-1 receptor agonists and dual agonists with clinical translation with Eli Lilly & Company and Boehringer Ingelheim to inform the next generation of oral incretins
Forged a pathway to clinical success in drug-based management of obesity with Regeneron and Aardvark Therapeutics in the wake of recent approvals to assess emerging surrogate endpoints
Navigated exciting progress in developing a small molecule oral therapy with Amgen and AltrixBio to drive easier and more sustainable access to diabetes and weight-loss therapies
Leveraged deep phenotyping, multi-omics, and analysis of biobank data with Copenhagen University and Novo Nordisk to elucidate metabolic dysfunction associated with obesity and drive holistic approaches to treatment
Defined a clinical pathway for small biotechs in the context of long and expensive cardiovascular outcome trials with Glyscend Therapeutics and Altimmune to elucidate options for cross-industry partnerships